Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology

British Journal of Haematology

Volumn 163, Issue 2, 2013, Pages 168-181

  Mcmillan, Andrew ^a   Ardeshna, Kirit M ^b   Cwynarski, Kate ^c   Lyttelton, Matthew ^d   Mckay, Pam ^e   Montoto, Silvia ^f  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d KETTERING GENERAL HOSPITAL   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Central nervous system; Chemotherapy; Intrathecal; Methotrexate; Non Hodgkin lymphoma

Indexed keywords

BLEOMYCIN; CARMUSTINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; HYDROCORTISONE; IDARUBICIN; IFOSFAMIDE; LACTATE DEHYDROGENASE; LOMUSTINE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE; VINDESINE;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARACHNOIDITIS; ARTICLE; BLOOD TOXICITY; BURKITT LYMPHOMA; CANCER GRADING; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM LYMPHOMA; CEREBROSPINAL FLUID ANALYSIS; CLINICAL DECISION MAKING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GASTROINTESTINAL TOXICITY; HEADACHE; HIGH RISK POPULATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MEDICAL SOCIETY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; SUSTAINED DRUG RELEASE; UNITED KINGDOM;

CENTRAL NERVOUS SYSTEM; CHEMOTHERAPY; INTRATHECAL; METHOTREXATE; NON-HODGKIN LYMPHOMA;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMOPREVENTION; HUMANS; RISK; TIME FACTORS;

EID: 84884973727     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12509     Document Type: Article

References (74)

1. Abramson, J.S., Hellmann, M., Barnes, J.A., Hammerman, P., Toomey, C., Takvorian, T., Muzikansky, A. & Hochberg, E.P. (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer, 116, 4283-4290.
2. Alvarez, R., Dupuis, J., Plonquet, A., Christov, C., Copie-Bergman, C., Hemery, F., Gaillard, I., El, G.T., Kuhnowski, F., Bedoui, M., Belhadj, K., Brugieres, P. & Haioun, C. (2012) Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma. Annals of Oncology, 23, 1274-1279.
3. Arkenau, H.T., Chong, G., Cunningham, D., Watkins, D., Agarwal, R., Sirohi, B., Trumper, M., Norman, A., Wotherspoon, A. & Horwich, A. (2007) The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Annals of Oncology, 18, 541-545.
4. Balis, F.M., Lester, C.M., Chrousos, G.P., Heideman, R.L. & Poplack, D.G. (1987) Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. Journal of Clinical Oncology, 5, 202-207.
5. Benevolo, G., Stacchini, A., Spina, M., Ferreri, A.J., Arras, M., Bellio, L., Botto, B., Bulian, P., Cantonetti, M., Depaoli, L., Di, R.N., Di, R.A., Evangelista, A., Franceschetti, S., Godio, L., Mannelli, F., Pavone, V., Pioltelli, P., Vitolo, U. & Pogliani, E.M. (2012) Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood, 120, 3222-3228.
6. Bernstein, S.H., Unger, J.M., Leblanc, M., Friedberg, J., Miller, T.P. & Fisher, R.I. (2009) Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 - the Southwest Oncology Group. Journal of Clinical Oncology, 27, 114-119.
7. van Besien, K., Ha, C.S., Murphy, S., McLaughlin, P., Rodriguez, A., Amin, K., Forman, A., Romaguera, J., Hagemeister, F., Younes, A., Bachier, C., Sarris, A., Sobocinski, K.S., Cox, J.D. & Cabanillas, F. (1998) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood, 91, 1178-1184.
8. Bjorkholm, M., Hagberg, H., Holte, H., Kvaloy, S., Teerenhovi, L., Anderson, H., Cavallin-Stahl, E., Myhre, J., Pertovaara, H., Ost, A., Nilsson, B. & Osby, E. (2007) Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Annals of Oncology, 18, 1085-1089.
9. Boehme, V., Zeynalova, S., Kloess, M., Loeffler, M., Kaiser, U., Pfreundschuh, M. & Schmitz, N. (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Annals of Oncology, 18, 149-157.
10. Boehme, V., Schmitz, N., Zeynalova, S., Loeffler, M. & Pfreundschuh, M. (2009) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood, 113, 3896-3902.
11. Bos, G.M., van Putten, W.L., van der Holt, B., van den Bent, M., Verdonck, L.F. & Hagenbeek, A. (1998) For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Annals of Oncology, 9, 191-194.
12. Brugieres, L., Le Deley, M.C., Rosolen, A., Williams, D., Horibe, K., Wrobel, G., Mann, G., Zsiros, J., Uyttebroeck, A., Marky, I., Lamant, L. & Reiter, A. (2009) Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. Journal of Clinical Oncology, 27, 897-903.
13. Burton, C., Smith, P., Vaughan-Hudson, G., Qian, W., Hoskin, P., Cunningham, D., Hancock, B. & Linch, D. (2005) Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. British Journal of Haematology, 130, 536-541.
14. Cetto, G.L., Iannucci, A., Tummarello, D., Rizzuto, N., Sabbioni, R. & Menestrina, F. (1981) Involvement of the central nervous system in non-Hodgkin's lymphoma. Tumori, 67, 39-44.
15. Cheung, C.W., Burton, C., Smith, P., Linch, D.C., Hoskin, P.J. & Ardeshna, K.M. (2005) Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. British Journal of Haematology, 131, 193-200.
16. Chua, S.L., Seymour, J.F., Streater, J., Wolf, M.M., Januszewicz, E.H. & Prince, H.M. (2002) Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leukemia & Lymphoma, 43, 1783-1788.
17. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
18. Dearden, C.E., Johnson, R., Pettengell, R., Devereux, S., Cwynarski, K., Whittaker, S. & McMillan, A. (2011) Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). British Journal of Haematology, 153, 451-485.
19. Department of Health. (2008) HSC 2008/001 Updated national guidance on the safe administration of intrathecal chemotherapy. Gateway ref: 10047 http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_086844.pdf.
20. Dollery, C. (1998) Therapeutic Drugs, 2nd edn. Churchill Livingstone, Oxford.
21. Doolittle, N.D., Abrey, L.E., Shenkier, T.N., Tali, S., Bromberg, J.E., Neuwelt, E.A., Soussain, C., Jahnke, K., Johnston, P., Illerhaus, G., Schiff, D., Batchelor, T., Montoto, S., Kraemer, D.F. & Zucca, E. (2008) Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood, 111, 1085-1093.
22. Evans, W.E., Hutson, P.R., Stewart, C.F., Cairnes, D.A., Bowman, W.P., Rivera, G. & Crom, W.R. (1983) Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clinical Pharmacology & Therapeutics, 33, 301-307.
23. Ferreri, A.J., Reni, M., Pasini, F., Calderoni, A., Tirelli, U., Pivnik, A., Aondio, G.M., Ferrarese, F., Gomez, H., Ponzoni, M., Borisch, B., Berger, F., Chassagne, C., Iuzzolino, P., Carbone, A., Weis, J., Pedrinis, E., Motta, T., Jouvet, A., Barbui, T., Cavalli, F. & Blay, J.Y. (2002) A multicenter study of treatment of primary CNS lymphoma. Neurology, 58, 1513-1520.
24. Ferreri, A.J., Guerra, E., Regazzi, M., Pasini, F., Ambrosetti, A., Pivnik, A., Gubkin, A., Calderoni, A., Spina, M., Brandes, A., Ferrarese, F., Rognone, A., Govi, S., Dell'Oro, S., Locatelli, M., Villa, E. & Reni, M. (2004) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. British Journal of Cancer, 90, 353-358.
25. Feugier, P., Virion, J.M., Tilly, H., Haioun, C., Marit, G., Macro, M., Bordessoule, D., Recher, C., Blanc, M., Molina, T., Lederlin, P. & Coiffier, B. (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Annals of Oncology, 15, 129-133.
26. Fonseca, R., Habermann, T.M., Colgan, J.P., O'Neill, B.P., White, W.L., Witzig, T.E., Egan, K.S., Martenson, J.A., Burgart, L.J. & Inwards, D.J. (2000) Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer, 88, 154-161.
27. Geisler, C.H., Kolstad, A., Laurell, A., Jerkeman, M., Raty, R., Andersen, N.S., Pedersen, L.B., Eriksson, M., Nordstrom, M., Kimby, E., Bentzen, H., Kuittinen, O., Lauritzsen, G.F., Nilsson-Ehle, H., Ralfkiaer, E., Ehinger, M., Sundstrom, C., Delabie, J., Karjalainen-Lindsberg, M.L., Brown, P. & Elonen, E. (2012) Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. British Journal of Haematology, 158, 355-362.
28. Gholam, D., Bibeau, F., El, W.A., Bosq, J. & Ribrag, V. (2003) Primary breast lymphoma. Leukemia & Lymphoma, 44, 1173-1178.
29. Guirguis, H.R., Cheung, M.C., Mahrous, M., Piliotis, E., Berinstein, N., Imrie, K.R., Zhang, L. & Buckstein, R. (2012) Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. British Journal of Haematology, 159, 39-49.
30. Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P. & Schunemann, H.J. (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 336, 924-926.
31. Haioun, C., Besson, C., Lepage, E., Thieblemont, C., Simon, D., Rose, C., Tilly, H., Sonet, A., Lederlin, P., Attal, M., Briere, J. & Reyes, F. (2000) Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Annals of Oncology, 11, 685-690.
32. Hegde, U., Filie, A., Little, R.F., Janik, J.E., Grant, N., Steinberg, S.M., Dunleavy, K., Jaffe, E.S., Abati, A., Stetler-Stevenson, M. & Wilson, W.H. (2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood, 105, 496-502.
33. Hollender, A., Kvaloy, S., Nome, O., Skovlund, E., Lote, K. & Holte, H. (2002) Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Annals of Oncology, 13, 1099-1107.
34. Joerger, M., Huitema, A.D., Krahenbuhl, S., Schellens, J.H., Cerny, T., Reni, M., Zucca, E., Cavalli, F. & Ferreri, A.J. (2010) Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. British Journal of Cancer, 102, 673-677.
35. Joerger, M., Ferreri, A.J., Krahenbuhl, S., Schellens, J.H., Cerny, T., Zucca, E. & Huitema, A.D. (2012) Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. British Journal of Clinical Pharmacology, 73, 240-247.
36. Kaspers, G.J., Veerman, A.J., Popp-Snijders, C., Lomecky, M., Van Zantwijk, C.H., Swinkels, L.M., Van Wering, E.R. & Pieters, R. (1996) Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Medical and Pediatric Oncology, 27, 114-121.
37. Keldsen, N., Michalski, W., Bentzen, S.M., Hansen, K.B. & Thorling, K. (1996) Risk factors for central nervous system involvement in non-Hodgkins-lymphoma-a multivariate analysis. Acta Oncologica, 35, 703-708.
38. Kim, T.D., Nogai, H., Dabritz, J.M., Schmitt, C.A., Dorken, B. & Pezzutto, A. (2011) Alternating high-dose methotrexate within R-CHOP21 is feasible in aggressive B-cell lymphoma patients at risk of CNS invlvement (Abstract). Annals of Oncology, 22 s4, iv194.
39. Kumar, A., Vanderplas, A., Lacasce, A.S., Rodriguez, M.A., Crosby, A.L., Lepisto, E., Czuczman, M.S., Nademanee, A., Niland, J., Gordon, L.I., Millenson, M., Zelenetz, A.D., Friedberg, J.W. & Abel, G.A. (2012) Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer, 118, 2944-2951.
40. Liang, R., Chiu, E. & Loke, S.L. (1990) Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematological Oncology, 8, 141-145.
41. MacKintosh, F.R., Colby, T.V., Podolsky, W.J., Burke, J.S., Hoppe, R.T., Rosenfelt, F.P., Rosenberg, S.A. & Kaplan, H.S. (1982) Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer, 49, 586-595.
42. McKay, P., Leach, M., Jackson, R., Cook, G. & Rule, S. (2012) Guidelines for the investigation and management of mantle cell lymphoma. British Journal of Haematology, 159, 405-426.
43. McMillan, A. (2005) Central nervous system-directed preventative therapy in adults with lymphoma. British Journal of Haematology, 131, 13-21.
44. Mead, G.M., Kennedy, P., Smith, J.L., Thompson, J., Macbeth, F.R., Ryall, R.D., Williams, C.J. & Whitehouse, J.M. (1986) Involvement of the central nervous system by non-Hodgkin's lymphoma in adults. A review of 36 cases. Quarterly Journal of Medicine, 60, 699-714.
45. Mead, G.M., Sydes, M.R., Walewski, J., Grigg, A., Hatton, C.S., Pescosta, N., Guarnaccia, C., Lewis, M.S., McKendrick, J., Stenning, S.P. & Wright, D. (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Annals of Oncology, 13, 1264-1274.
46. Mikkelsen, T.S., Sparreboom, A., Cheng, C., Zhou, Y., Boyett, J.M., Raimondi, S.C., Panetta, J.C., Bowman, W.P., Sandlund, J.T., Pui, C.H., Relling, M.V. & Evans, W.E. (2011) Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. Journal of Clinical Oncology, 29, 1771-1778.
47. Millot, F., Suciu, S., Philippe, N., Benoit, Y., Mazingue, F., Uyttebroeck, A., Lutz, P., Mechinaud, F., Robert, A., Boutard, P., Marguerite, G., Ferster, A., Plouvier, E., Rialland, X., Behard, C., Plantaz, D., Dresse, M.F., Philippet, P., Norton, L., Thyss, A., Dastugue, N., Waterkeyn, C., Vilmer, E. & Otten, J. (2001) Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. Journal of Clinical Oncology, 19, 1935-1942.
48. Mitrovic, Z., Bast, M., Bierman, P.J., Bociek, R.G., Vose, J.M., Chan, W.C. & Armitage, J.O. (2012) The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. British Journal of Haematology, 157, 401-403.
49. Montoto, S. & Lister, T.A. (2005) Secondary central nervous system lymphoma: risk factors and prophylaxis. Hematology/Oncology Clinics of North America, 19, 751-763, viii.
50. Nathan, P.C., Whitcomb, T., Wolters, P.L., Steinberg, S.M., Balis, F.M., Brouwers, P., Hunsberger, S., Feusner, J., Sather, H., Miser, J., Odom, L.F., Poplack, D., Reaman, G. & Bleyer, W.A. (2006) Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P. Leukemia & Lymphoma, 47, 2488-2504.
51. NICE. (2003) Rituximab for Aggressive Non-Hodgkin Lymphoma: Technology Appraisal 65. National Institute for Clinical Excellence, London.
52. Perez-Soler, R., Smith, T.L. & Cabanillas, F. (1986) Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. Cancer, 57, 971-977.
53. Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A.C., Rudolph, C., Reiser, M., Hossfeld, D.K., Metzner, B., Hasenclever, D., Schmitz, N., Glass, B., Rube, C. & Loeffler, M. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood, 104, 626-633.
54. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, 7, 379-391.
55. Recher, C., Coiffier, B., Haioun, C., Molina, T.J., Ferme, C., Casasnovas, O., Thieblemont, C., Bosly, A., Laurent, G., Morschhauser, F., Ghesquieres, H., Jardin, F., Bologna, S., Fruchart, C., Corront, B., Gabarre, J., Bonnet, C., Janvier, M., Canioni, D., Jais, J.P., Salles, G. & Tilly, H. (2011) Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet, 378, 1858-1867.
56. Rubenstein, J.L., Combs, D., Rosenberg, J., Levy, A., McDermott, M., Damon, L., Ignoffo, R., Aldape, K., Shen, A., Lee, D., Grillo-Lopez, A. & Shuman, M.A. (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood, 101, 466-468.
57. Schmiegelow, K. (2009) Advances in individual prediction of methotrexate toxicity: a review. British Journal of Haematology, 146, 489-503.
58. Schulz, H., Pels, H., Schmidt-Wolf, I., Zeelen, U., Germing, U. & Engert, A. (2004) Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica, 89, 753-754.
59. Shimazu, Y., Notohara, K. & Ueda, Y. (2009) Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. International Journal of Hematology, 89, 577-583.
60. Shipp, M.A., Yeap, B.Y., Harrington, D.P., Klatt, M.M., Pinkus, G.S., Jochelson, M.S., Rosenthal, D.S., Skarin, A.T. & Canellos, G.P. (1990) The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. Journal of Clinical Oncology, 8, 84-93.
61. Tai, W.M., Chung, J., Tang, P.L., Koo, Y.X., Hou, X., Tay, K.W., Quek, R., Tao, M. & Lim, S.T. (2011) Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Annals of Hematology, 90, 809-818.
62. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329, 987-994.
63. Tilly, H., Lepage, E., Coiffier, B., Blanc, M., Herbrecht, R., Bosly, A., Attal, M., Fillet, G., Guettier, C., Molina, T.J., Gisselbrecht, C. & Reyes, F. (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 102, 4284-4289.
64. Tomita, N., Kodama, F., Kanamori, H., Motomura, S. & Ishigatsubo, Y. (2002) Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma. Cancer, 95, 576-580.
65. Tubergen, D.G., Gilchrist, G.S., O'Brien, R.T., Coccia, P.F., Sather, H.N., Waskerwitz, M.J. & Hammond, G.D. (1993) Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. Journal of Clinical Oncology, 11, 520-526.
66. Villa, D., Connors, J.M., Shenkier, T.N., Gascoyne, R.D., Sehn, L.H. & Savage, K.J. (2010) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Annals of Oncology, 21, 1046-1052.
67. Vitolo, U., Chiappella, A., Ferreri, A.J., Martelli, M., Baldi, I., Balzarotti, M., Bottelli, C., Conconi, A., Gomez, H., Lopez-Guillermo, A., Martinelli, G., Merli, F., Novero, D., Orsucci, L., Pavone, V., Ricardi, U., Storti, S., Gospodarowicz, M.K., Cavalli, F., Sarris, A.H. & Zucca, E. (2011) First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. Journal of Clinical Oncology, 29, 2766-2772.
68. Woessmann, W., Seidemann, K., Mann, G., Zimmermann, M., Burkhardt, B., Oschlies, I., Ludwig, W.D., Klingebiel, T., Graf, N., Gruhn, B., Juergens, H., Niggli, F., Parwaresch, R., Gadner, H., Riehm, H., Schrappe, M. & Reiter, A. (2005) The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood, 105, 948-958.
69. Wolfrom, C., Hartmann, R., Fengler, R., Bruhmuller, S., Ingwersen, A. & Henze, G. (1993) Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 11, 827-833.
70. Yamamoto, W., Tomita, N., Watanabe, R., Hattori, Y., Nakajima, Y., Hyo, R., Hashimoto, C., Motomura, S. & Ishigatsubo, Y. (2010) Central nervous system involvement in diffuse large B-cell lymphoma. European Journal of Haematology, 85, 6-10.
71. Zinzani, P.L., Martelli, M., Storti, S., Musso, M., Cantonetti, M., Leone, G., Cajozzo, A., Papa, G., Iannitto, E., Perrotti, A., Bendandi, M., Gherlinzoni, F., Gentilini, P., Rossi, G., Aitini, E., Mandelli, F. & Tura, S. (1995) Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leukemia & Lymphoma, 19, 329-335.
72. Zinzani, P.L., Magagnoli, M., Frezza, G., Prologo, G., Gherlinzoni, F., Bendandi, M., Albertini, P., Babini, L., D'Alessandro, R. & Tura, S. (1999) Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leukemia & Lymphoma, 32, 571-576.
73. Zucca, E., Roggero, E., Bertoni, F., Conconi, A. & Cavalli, F. (1999) Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Annals of Oncology, 10, 1023-1033.
74. Zucca, E., Conconi, A., Mughal, T.I., Sarris, A.H., Seymour, J.F., Vitolo, U., Klasa, R., Ozsahin, M., Mead, G.M., Gianni, M.A., Cortelazzo, S., Ferreri, A.J., Ambrosetti, A., Martelli, M., Thieblemont, C., Moreno, H.G., Pinotti, G., Martinelli, G., Mozzana, R., Grisanti, S., Provencio, M., Balzarotti, M., Laveder, F., Oltean, G., Callea, V., Roy, P., Cavalli, F. & Gospodarowicz, M.K. (2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. Journal of Clinical Oncology, 21, 20-27.